RxDoctor Payments Data

Tiffany Diaz, APRN

Psychiatric/Mental Health · Fort Smith, ARNPI 1962094565

Payments from drug & device makers

$1,155in general payments, 2019–2025

Across 123 payments — averaging $9.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$855
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$107
  • Neurocrine Biosciences, Inc.$98
  • Johnson & Johnson$52
  • Eisai Inc.$16
  • Axsome Therapeutics, Inc.$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$1,155100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,155 in reported general payments places this provider in the 55th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$20,171
Medicare patients
61
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate22$175,944
VraylarCariprazine Hcl47$69,351
CaplytaLumateperone Tosylate22$36,129
TrintellixVortioxetine Hydrobromide26$16,934
Atomoxetine Hcl29$3,207
Lurasidone Hcl24$2,869
Bupropion XlBupropion Hcl101$1,743
Duloxetine Hcl82$1,608
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$1,504
Buspirone Hcl153$1,484
Venlafaxine Hcl ErVenlafaxine Hcl62$1,335
Fluoxetine Hcl140$1,112
Quetiapine Fumarate84$1,020
Hydroxyzine Hcl60$975
Clonazepam168$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$98$175,94422 claims
AbbVieVraylar$855$69,35147 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$107$36,12922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →